Pharmaceutical Market Research Conference 2020 round-up
Earlier this month Director, Head of NY Office, Liza Pliss and Director, Head of Philadelphia Office, Head of MedTech Division, Sabera Hyderally attended the Pharmaceutical Market Research Conference in Newark, New Jersey.
Conducting research in Latin America
Paul Reed explores the opportunities in this exciting region, which has diverse and unique healthcare systems, an ageing and declining population, and a rise in the popularity of digital communication channels, especially WhatsApp.
Infographic: Research Partnership
Did you know that we conduct over 300 projects a year in over 70 countries and covering more than 80 therapy areas?
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
3 trends the healthcare market research industry should watch out for over the next decade
As we head into the 2020s, Associate Director Ellie Forde considers the key trends that might impact healthcare over the next 10 years and the possible impacts on market research.
My colleague Rachel Howard wrote a blog at the end of last year reviewing her predictions in 2010 for the coming decade. As we head into the 2020s, I thought it might be timely to consider the key trends that might impact healthcare over the next 10 years. With technology advancing at an ever-increasing pace, these may be many, but I want to focus on what I believe are three of the big ‘watch outs’, and those I am personally excited about.
How we helped determine the next groundbreaking development in a hard-to-treat respiratory disease
Our client wanted to understand the current management in a complex therapy area, as treatment regimens require a combination of multiple drugs. Furthermore, the disease is most prevalent in emerging, hard-to-access markets. Understanding of drugs and treatment regimen preferences were required to help gauge likely success of the client’s new formulation in development, which would be part of a new regimen paradigm. As well as understanding current preferences and reactions to the new drug and regimen, the research needed to test several potential outcomes for the new formulation and assess performance against future new regimens likely to be available at the time of launch.